All News
Effective Treatments for Rheumatoid Arthritis ILD
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Read Article
The Lupus APOL1 Story
Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
Dr. John Cush RheumNow ( View Tweet)
ROMO vs DEN.
Romosozumab was superior to denosumab
(ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk
Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me
Dr. Antoni Chan ( View Tweet)
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Janet Pope ( View Tweet)
Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly.
Gene expression signatures might tell us more - one key cluster here was 21x predictive.
#ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC
David Liew drdavidliew ( View Tweet)
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Md Yuzaiful Md Yusof ( View Tweet)
During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations.
⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM
➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
HCQ and risk of retinopathy 👁️
DoD database HCQ 44000+ females & 10000+ males
Risk retinopathy HR 1.5
Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7
No adjustment on HCQ dose
@RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Aurelie Najm ( View Tweet)
@md_chawla @RheumNow https://t.co/PVxox5t8ZH
Links:
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
@md_chawla @RheumNow https://t.co/qSdT7by1Vh
Links:
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0
Bella Mehta bella_mehta ( View Tweet)
#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J
Md Yuzaiful Md Yusof ( View Tweet)
And to continue
B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years
4000+ pts, 3% retinopathy over 5yrs
Predictors of HCQ retinopathy
-body weight
-sex
-age
-eGFR
-weight based dose mg/kg
-higher cumulative dose
Risk ranges 1% to >20%
@RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0
Aurelie Najm ( View Tweet)
Very nice to meet @KDAO2011 and @uptoTate as the faculty of Rheum Now @RheumNow tune in, follow them and listen to their interviews on the latest updates from #ACR23 https://t.co/I30wdVoqbd
Dr. Antoni Chan ( View Tweet)
Synovitis in hand #OA
genetic
risk of synovitis predisposed to clinical and radiographic hand OA
@RheumNow #ACR23 https://t.co/aXnXD7UPnv
Bella Mehta bella_mehta ( View Tweet)
Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia
Having the dual skill set actually helped with adherence to guidelines vs standard care. Would be great to see how this works with implementation in RA clinics
#ACR23 ABST2484 @RheumNow https://t.co/88R1BYzYn5
David Liew drdavidliew ( View Tweet)
#ACR23 Abstr# 2490 Data supporting aggressive early treatment in #SLE? Multicentre open label RCT in China showed low dose MMF + Pred 0.5mg/kg/d reduced severe flare & lupus nephritis cases vs HCQ + Pred in new onset SLE with high dsDNA but w/o major organ involvement @RheumNow https://t.co/oRlgCaOvXo
Md Yuzaiful Md Yusof ( View Tweet)
Watch: Utility of AI and ChatGPT in Rheumatology
Dr. Kathryn Dao interviews Dr. Richard Stern at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/SH0TGAdvm8 https://t.co/RHu8bH9YOG
Dr. John Cush RheumNow ( View Tweet)
TM86 #ACR23 @RheumNow
Auricular chondritis, arthritis, axonopathy, high inflamm. Initial Dx: RP
Exam: lymphadenopathy, erythema nodosum, TJC 36, SJC 4 (knees/ankles), decr sensation, asymm reflex, macular rash, nerve thicken
Skin bx: septal panniculitis wo vasc
Dx: leprosy https://t.co/P5QJArRDaA
Eric Dein ( View Tweet)
#Cardiovascular imaging will help to detect #cardiac abnormalities earlier@in #rheumatic #diseases. #ACR23 @RheumNow @ACRheum 14T118 https://t.co/QKCpLWtkUv
Janet Pope ( View Tweet)